WO2006119589A3 - Prevention and therapy of cerebral folate deficiency - Google Patents

Prevention and therapy of cerebral folate deficiency Download PDF

Info

Publication number
WO2006119589A3
WO2006119589A3 PCT/BE2006/000045 BE2006000045W WO2006119589A3 WO 2006119589 A3 WO2006119589 A3 WO 2006119589A3 BE 2006000045 W BE2006000045 W BE 2006000045W WO 2006119589 A3 WO2006119589 A3 WO 2006119589A3
Authority
WO
WIPO (PCT)
Prior art keywords
cfd
5mthf
autoantibodies
major
prevention
Prior art date
Application number
PCT/BE2006/000045
Other languages
French (fr)
Other versions
WO2006119589A2 (en
Original Assignee
Ramaekers Vincent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramaekers Vincent filed Critical Ramaekers Vincent
Publication of WO2006119589A2 publication Critical patent/WO2006119589A2/en
Publication of WO2006119589A3 publication Critical patent/WO2006119589A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pediatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to methods and means to prevent CFD and/or to treat CFD at a very early stage, when CFD has not yet fully developed. It was found that circulating and blocking autoantibodies to FR represent one of the major causes of CFD and that prognosis improves the younger a child can be treated. The invention as such in particular relates to a method of screening infants and their mothers for the presence of circulating autoantibodies in their serum and/or for low 5MTHF CSF levels, followed by a prompt treatment of a subject in need thereof with a folate supplement in case the testing procedure is positive. Such screening should also be performed for all children or any other subjects as soon as at least 3 of the major criteria of CFD manifest. It was further found that the addition of antioxidants to a folate supplement maintains stability of 5MTHF and can help restore an impaired 5MTHF uptake in the nervous system due to the circulation of blocking autoantibodies. Avoidance of foods and products, containing proteins with similar amino acid sequences as compared to human FRs, is strongly preferred in the preparation of compounds or food products for the prevention and/or treatment of CFD. The methods and means of the invention have a major impact on the health of the population and can help to reduce the incidence of for instance autism and schizophrenia related to CFD.
PCT/BE2006/000045 2005-05-11 2006-05-04 Prevention and therapy of cerebral folate deficiency WO2006119589A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2005000074 2005-05-11
BEPCT/BE2005/00074 2005-05-11

Publications (2)

Publication Number Publication Date
WO2006119589A2 WO2006119589A2 (en) 2006-11-16
WO2006119589A3 true WO2006119589A3 (en) 2007-07-26

Family

ID=37111756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2006/000045 WO2006119589A2 (en) 2005-05-11 2006-05-04 Prevention and therapy of cerebral folate deficiency

Country Status (1)

Country Link
WO (1) WO2006119589A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7286631B2 (en) 2017-09-29 2023-06-05 アプロフォル アクチエンゲゼルシャフト folate for medical use

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983057A (en) 2008-01-30 2011-03-02 新加坡科技研究局 Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
EP2803356A1 (en) * 2008-03-31 2014-11-19 Agency for Science, Technology and Research Method for treating neurological disorders with imidazolium and imidazolinium compounds
EP2253266A1 (en) 2009-05-22 2010-11-24 Assistance Publique - Hôpitaux de Paris Method for treating patients with cerebral calcifications
CA3031481C (en) * 2009-07-10 2021-03-16 Linzy O. Scott, Iii Methods and compositions for treating thyroid-related medical conditions with reduced folates
US20120004238A1 (en) * 2010-07-01 2012-01-05 Quillin Robert L L-methylfolate treatment for psychiatric or neurologic disorders
WO2016135707A1 (en) * 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
WO2017112588A1 (en) * 2015-12-21 2017-06-29 Abbott Laboratories Liquid nutritional composition containing 5-methyltetrahydrofolic acid
WO2017218632A1 (en) * 2016-06-14 2017-12-21 Board Of Regents, The University Of Texas System Methods of detecting anti-folic acid antibodies and uses thereof
CN106841426A (en) * 2016-12-30 2017-06-13 广州市达瑞生物技术股份有限公司 A kind of human serum folic acid and its metabolin tandem mass spectrum detection kit
WO2019238998A1 (en) * 2018-06-13 2019-12-19 Servicio Andaluz De Salud Use of antioxidants for the treatment of depression in older patients
RU2712146C1 (en) * 2019-08-23 2020-01-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации Method of antioxidant status correction in children epilepsy monotherapy
CA3190147A1 (en) * 2020-07-27 2022-02-03 George AYOUB Methods of reducing incidence or risk of cerebral folate deficiency

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0898965A2 (en) * 1997-06-13 1999-03-03 EPROVA Aktiengesellschaft Use of tetrahydrofolates for modulating the homocysteine level
US6093703A (en) * 1990-10-23 2000-07-25 Bioresearch S.P.A. Pharmaceutical compositions, containing S-adenosyl-L-methionine salt, 5-methyl-tetrahydrofolic acid and 5-formyltetrahydrofolic acid
WO2001084962A2 (en) * 2000-05-10 2001-11-15 Basf Aktiengesellschaft Compositions containing folic acid and reduced folate
US20040219262A1 (en) * 1996-01-31 2004-11-04 Bailey Steven W. Food and vitamin preparations containing the natural isomer of reduced folates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093703A (en) * 1990-10-23 2000-07-25 Bioresearch S.P.A. Pharmaceutical compositions, containing S-adenosyl-L-methionine salt, 5-methyl-tetrahydrofolic acid and 5-formyltetrahydrofolic acid
US20040219262A1 (en) * 1996-01-31 2004-11-04 Bailey Steven W. Food and vitamin preparations containing the natural isomer of reduced folates
EP0898965A2 (en) * 1997-06-13 1999-03-03 EPROVA Aktiengesellschaft Use of tetrahydrofolates for modulating the homocysteine level
WO2001084962A2 (en) * 2000-05-10 2001-11-15 Basf Aktiengesellschaft Compositions containing folic acid and reduced folate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOSCIENCE REPORTS 2002 JUN-AUG, vol. 22, no. 3-4, June 2002 (2002-06-01), pages 431 - 441, ISSN: 0144-8463 *
BIOSCIENCE REPORTS 2003 APR-JUN, vol. 23, no. 2-3, April 2003 (2003-04-01), pages 77 - 85, ISSN: 0144-8463 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; April 2003 (2003-04-01), HOLM JAN ET AL: "Ligand binding and polymerization characteristics of human milk folate binding protein depend on concentration of purified protein and presence of amphiphatic substances.", XP002433261, Database accession no. NLM14570378 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 2002 (2002-06-01), HOLM JAN ET AL: "Ligand binding characteristics and aggregation behavior of purified cow's milk folate binding protein depends on the presence of amphiphatic substances including cholesterol, phospholipids, and synthetic detergents.", XP002433262, Database accession no. NLM12516784 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7286631B2 (en) 2017-09-29 2023-06-05 アプロフォル アクチエンゲゼルシャフト folate for medical use

Also Published As

Publication number Publication date
WO2006119589A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
WO2006119589A3 (en) Prevention and therapy of cerebral folate deficiency
Villa et al. Bovine milk allergens: A comprehensive review
Xia et al. Chronic exposure to low concentrations of lead induces metabolic disorder and dysbiosis of the gut microbiota in mice
Susheela et al. Excess fluoride ingestion and thyroid hormone derangements in children living in Delhi, India
RU2481008C2 (en) Composition of nutritional powder and infant nutritional mixture (versions)
Schroecksnadel et al. Hyperhomocysteinemia and immune activation
Scheinberg et al. Is non-Indian childhood cirrhosis caused by excess dietary copper?
WO2007029008A3 (en) Method of treatment or prevention of age-related macular degeneration
Seo et al. Effects of voluntary exercise on apoptosis and cortisol after chronic restraint stress in mice
Klaveness et al. The varied rate of response to dietary intervention in autistic children
Trefz et al. Final intelligence in late treated patients with phenylketonuria
Veiga et al. Accumulation, elimination, and effects of parenteral exposure to aluminum in newborn and adult rats
Ahring et al. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model
US20210379145A1 (en) Compositions for increasing resilience to traumatic brain injury
Blaylock The danger of excessive vaccination during brain development the case for a link to autism spectrum disorders
Foster How aluminum causes Alzheimer's disease: the implications for prevention and treatment of Foster's multiple antagonist hypothesis
Chien Ethosuximide-induced mania in a 10-year-old boy
Ghasemzadeh et al. Effectiveness of coping skills on depression, anxiety and stress in mothers of adolescents with type I diabetes
Chauhan et al. Contribution of oxidative stress to the pathophysiology of autism spectrum disorders: impact of genetic and environmental factors
MacDonald 5-Methyltetrahydrofolate vs. folic acid: which is the optimal choice for human health?
Spero et al. Effects of maternal hyperphenylalaninemia on fetal brain development: a biochemical study
Al-Sultan et al. Residual Levels of Toxic Metals and Estimation of their Dietary Intakes, and Non-Carcinogenic Risks Associated with the Consumption of Meat and Edible Offal of Camel in Egypt and Saudi Arabia
Najafi Protective effects of long term administration of zinc on bone metabolism parameters in male Wistar rats treated with cadmium
Morshdy et al. Heavy metal contents in salted fish retailed in Egypt: Dietary intakes and health risk assessment
Ostojic et al. The effects of two different creatine formulations on muscle bioenergetics in men.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06741300

Country of ref document: EP

Kind code of ref document: A2